Patients with lichen sclerosus experience moderate satisfaction with treatment and impairment of quality of life: results of a cross‐sectional study. (1st June 2017)

• Record Type: Journal Article
• Authors: van Cranenburgh, O.D.; Nijland, S.B.W.; Lindeboom, R.; de Korte, J.; de Rie, M.A.; ter Stege, J.A.; Prinsen, C.A.C.
• Is Part Of: British journal of dermatology. Volume 176:Number 6(2017)
• Page Start: 1508
• Page End: 1515
• Publication Date: 2017-06-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.15125
• Languages: English
• ISSNs: 0007-0963

Abstract

Summary: Background: Although they are considered relevant, little is known about satisfaction with treatment and health‐related quality of life (HRQoL) among patients with lichen sclerosus (LS). Objectives: In a cross‐sectional study, we aimed to examine (i) satisfaction with treatment, (ii) patient characteristics associated with satisfaction and (iii) HRQoL in Dutch patients with LS. Methods: Members of the Dutch LS Patient Association ( n = 750) were invited to complete a web‐based survey. We measured satisfaction with treatment with a study‐specific questionnaire, and HRQoL with the Skindex‐29. We calculated domain scores for symptoms, emotions and functioning, and categorized scores into little, mildly, moderately or severely impaired HRQoL. We used a multiple linear regression analysis to examine whether patient characteristics were associated with treatment satisfaction. Results: In total 303 patients (40·4%) were included. Patients under current treatment ( n = 265, 87·5%) were moderately satisfied with their treatment. Patients rated 'treatment effectiveness' as most important, although 58 (22%) were dissatisfied with the effectiveness of their current treatment. More impairment on the HRQoL emotions domain and a higher degree of disease severity were both associated with lower satisfaction with treatment and explained in total 13·5% of the variance in treatment satisfaction. On all HRQoL domains, one‐third of the patients (range 34·7–38·9%) reported severe impairment. Conclusions: Patients with LS are moderately satisfied with their treatment, and one‐third of patients experience severe impairment of HRQoL. To improve dermatological care, we recommend enhancement of doctor–patient communication, information provision and organization, which may be more amenable to change than treatment effectiveness or safety.